ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
Ascidian Therapeutics
Ascidian Therapeutics, Inc. is seeking a Principal Associate Scientist to design, validate, and execute experiments that enhance the therapeutic performance of designer RNA editing molecules. The role involves contributing to the characterization of drug candidates to support the company's collaboration with Roche. This position requires expertise in RNA therapeutics, including pre-mRNA splicing, protein translation, and the development of custom Illumina libraries.
Headquarters
Boston, Massachusetts, United States
Company Size
11-50 employees
Founded
2020
Ascidian Therapeutics is a biotechnology company developing exon‑editing RNA therapeutics to target the underlying causes of disease. The company leverages RNA‑based exon editing to modulate splicing and correct disease‑causing transcripts with the goal of creating precise, durable treatments. Positioned as an innovator in RNA therapeutics, Ascidian focuses on translating its platform into targeted medicines for genetically driven disorders.
Business WireAscidian Therapeutics and Forge Biologics Announce Manufacturing Partnership to Advance RNA Editing Therapy for Stargardt Disease
Jan 7, 2026
PR NewswireAscidian Therapeutics Appoints Dr. Murray A. Abramson as Chief Development Officer and Establishes Ophthalmology Clinical Advisory Board to Advance ACDN-01 for Treatment of Stargardt Disease
Jun 24, 2025
Contract PharmaAscidian Therapeutics, Forge Biologics Partner to Advance Stargardt Treatment
Jan 7, 2026
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Ascidian Therapeutics.
16% below the average for this role
PR NewswireAscidian Therapeutics Announces Formation of Scientific Advisory Board
May 6, 2025
Post Doctoral Scholar
The Ohio State University
PhD scholarship in Multi-target acute GPCR inhibitors for migraine delivered via intranasal mRNA-encoded binders - DTU Bioengineering
Oracle
Research Associate I- Ramani Lab
Gladstone Institutes
PhD scholarship in Multi-target acute GPCR inhibitors for migraine delivered via intranasal mRNA-encoded binders - DTU Bioengineering
Oracle
Senior RNA Chemist – RNA Therapeutics
Amgen
Post Doctoral Scholar
The Ohio State University
